Abatacept for children with CVID and lung scarring
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This Phase 2 trial tests abatacept to improve a specific type of lung disease in children with common variable immunodeficiency (CVID). It aims to slow or reduce ongoing lung changes seen on CT scans while they continue their usual immune “replacement” therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 4 or older and have been diagnosed with CVID based on standard immune blood tests
- Your immunoglobulin blood levels (IgG low, plus low IgA and/or IgM) and vaccine response fit CVID
- You must already be on immune globulin replacement (for example, IVIG/SCIG) for at least 6 months and keep it during the study
- You have granulomatous-lymphocytic interstitial lung disease confirmed by lung biopsy (wedge biopsy preferred)
- Your lung CT scans must show the lung disease is still present or getting worse, with scans at least 6 months apart (latest within 3 months)
- You can take injections at home and agree to contraception if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests if a combination of three drugs (azithromycin, hydroxychloroquine, and prednisone) can help people with a genetic form of lung scarring. The goal is to see if these medicines calm the immune system and slow down the disease.
This trial looks at how breathing tests (spirometry) can help guide treatment decisions for people with CVID and airway disease who are already on immune globulin (IG) therapy. It may help your care team better monitor lung function using a specific breathing-test pattern.
This Phase 3 trial tests abatacept to treat myocarditis (inflammation of the heart muscle) caused by immune checkpoint cancer medicines. It may help patients recover faster and safely manage this serious side effect while they are in the hospital.
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
This trial tests whether adding abatacept to standard care can reduce graft-versus-host disease (a condition where donor cells attack your body) after a stem cell transplant using a special cord blood product called omidubicel. It is for adults with blood cancers who have a suitable cord blood unit available.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.